CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model

International Journal of Cancer

Volumn 129, Issue 1, 2011, Pages 225-232

  Hassan, Saima ^a   Buchanan, Marguerite ^a   Jahan, Kaushar ^a   Aguilar Mahecha, Adriana ^a   Gaboury, Louis ^b   Muller, William J ^c   Alsawafi, Yaqoob ^a   Mourskaia, Anna A ^c   Siegel, Peter M ^c   Salvucci, Ombretta ^d   Basik, Mark ^a  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

breast cancer; CXCR4; metastasis; primary tumor; therapeutic target; transgenic mouse

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; DOCETAXEL; MONOCLONAL ANTIBODY DC101; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GROWTH RATE; MALE; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SINGLE DRUG DOSE; TRANSGENIC MOUSE; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; PEPTIDES; RECEPTORS, CXCR4; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955445350     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25665     Document Type: Article

References (35)

1. Weinberg RA,. The biology of cancer. New York: Garland Science, 2007. 591 p.
2. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6. (Pubitemid 32225831)
3. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M,. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006; 97: 275-83. (Pubitemid 43945757)
4. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA,. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48. (Pubitemid 40692295)
5. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H,. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64: 4302-8. (Pubitemid 38802437)
6. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD,. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-12. (Pubitemid 39552073)
7. Sharpless NE, Depinho RA,. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5: 741-54. (Pubitemid 44323701)
8. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008; 25: 201-11.
9. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ,. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009; 69: 1460-9.
10. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A,. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155: 231-6.
11. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR,. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009; 21: 761-7.
12. Wong D, Korz W,. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008; 14: 7975-80.
13. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW,. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163: 2113-26. (Pubitemid 37310040)
14. Wang Z, Storm DR,. Extraction of DNA from mouse tails. Biotechniques 2006; 41: 410, 12.
15. Kim LS, Price JE,. Clinically relevant metastatic breast cancer models to study chemosensitivity. Methods Mol Med 2005; 111: 285-95.
16. Wong D, Korz W, Salari H,. Anticancer effect of a combination of CXCR4 antagonist CTCE-9908 and Docetaxel in a murine model of human prostate cancer. In: Proceedings of the AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, San Francisco, California. October 22-26, 2007. (Abstract C20).
17. Dykes DJ, Bissery MC, Harrison SD, Jr., Waud WR,. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995; 13: 1-11.
18. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW,. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998; 77: 640-4. (Pubitemid 28340915)
19. Bachelder RE, Wendt MA, Mercurio AM,. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-6. (Pubitemid 36025239)
20. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H,. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007; 359: 716-22. (Pubitemid 46908803)
21. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14: 263-73.
22. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ,. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154: 1125-35. (Pubitemid 29169747)
23. Feil C, Augustin HG,. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochem Biophys Res Commun 1998; 247: 38-45. (Pubitemid 28412521)
24. Fenton BM, Paoni SF, Ding I,. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res 2004; 64: 5712-9. (Pubitemid 39095569)
25. Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM,. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther 2004; 3: 969-76. (Pubitemid 39199591)
26. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA,. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893-902. (Pubitemid 39434977)
27. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D,. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006; 66: 8770-8. (Pubitemid 44449194)
28. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE,. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005; 65: 6493-7. (Pubitemid 41060680)
29. Loges S, Mazzone M, Hohensinner P, Carmeliet P,. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-70.
30. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS,. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
31. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O,. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
32. Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F,. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 2009; 8: 1893-905.
33. Jain RK, Duda DG, Clark JW, Loeffler JS,. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40. (Pubitemid 43108832)
34. Cannistra SA,. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008; 26: 3665-7.
35. Popat S, Smith IE,. Therapy Insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 2008; 5: 324-35. (Pubitemid 351780949)